Verition Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Verition Fund Management's XENE Position: Q3 2026 in Review
Verition Fund Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 40,000 shares — an estimated $2.41M sold.
Verition Fund Management first reported a position in XENE in Q4 2024 and held it in 6 quarters. The position peaked at $4.2M in Q4 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Verition Fund Management reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Verition Fund Management sold 40,000 Xenon Pharmaceuticals shares in Q3 2026, an estimated $2.41M.
- Verition Fund Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and held it in 6 quarters.
- Verition Fund Management's Xenon Pharmaceuticals position peaked at $4.2M in Q4 2025.
- 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.